Understanding the Surge – ILMN's Stock Performance Today

Illumina stock is trading -13.5% below its average target price of $154.86 after marking a 2.9% during today's morning session. Analysts are giving the Large-Cap Medical Specialities company an average rating of buy and target prices ranging from $85.0 to $258.0 per share.

Illumina's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 3.5%. The stock's short ratio is 2.8. The company's insiders own 0.27% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 94.5%. In conclusion, we believe there is mixed market sentiment regarding Illumina.

Institutions Invested in Illumina

Date Reported Holder Percentage Shares Value
2023-12-31 Vanguard Group Inc 11% 18,178,513 $2,435,099,136
2023-12-31 Blackrock Inc. 8% 13,302,999 $1,782,000,616
2023-12-31 Edgewood Management Llc 4% 6,878,495 $921,407,445
2023-12-31 State Street Corporation 4% 6,723,616 $900,660,659
2023-12-31 Baillie Gifford and Company 3% 5,275,769 $706,714,599
2023-12-31 Loomis Sayles & Company, LP 3% 4,424,688 $592,708,211
2023-12-31 Janus Henderson Group PLC 3% 4,402,380 $589,719,947
2023-12-31 Morgan Stanley 2% 3,698,229 $495,395,538
2023-12-31 Geode Capital Management, LLC 2% 3,634,176 $486,815,331
2023-12-31 Wellington Management Group, LLP 2% 3,239,021 $433,882,421
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.